Premium
Nivolumab for relapsed or refractory H odgkin lymphoma: Experience in T urkey
Author(s) -
Ferhanoglu B.,
Bekoz H.,
Karadurmus N.,
Paydas S.,
Gulbas Z.,
Turker A.,
Toptas T.,
Firatli Tuglular T.,
Tekgunduz E.,
Kaya A.,
Tastemir N.,
Arat M.,
Pepedil Tanrikulu F.,
Ozkocaman V.,
Abali H.,
Turgut M.,
Kaynar L.,
Karadogan I.,
Ozbalak M.,
Dogu M.,
Kabukcu Hacioglu S.,
Yildirim R.,
Barista I.,
Kurt Yuksel M.,
Sonmez M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_63
Subject(s) - medicine , nivolumab , brentuximab vedotin , refractory (planetary science) , radiological weapon , surgery , oncology , lymphoma , hodgkin lymphoma , immunotherapy , cancer , physics , astrobiology